Larimar Therapeutics
LRMR
43 hedge funds and large institutions have $305M invested in Larimar Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
48% more capital invested
Capital invested by funds: $207M → $305M (+$98.4M)
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
13% more funds holding
Funds holding: 38 → 43 (+5)
4.08% more ownership
Funds ownership: 88.7% → 92.79% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.72M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.81M |
| 3 |
BlackRock
New York
|
+$3.11M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$1.45M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.19M |
| 2 |
SCM
Sio Capital Management
New York
|
-$2.24M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.22M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.16M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$914K |
LRMR Hedge Fund Activity: Q4 2020 in Review
43 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2020, worth a combined $305M — up 48% from $207M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new LRMR positions and 6 closed out — a net gain of 5 holders — while 11 added to existing stakes and 8 trimmed.
The largest buyer was Logos Global Management, adding an estimated $7.72M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.19M sold.
- 43 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2020, up from 38 in Q3 2020.
- Funds reported $305M of Larimar Therapeutics stock for Q4 2020, up 48% quarter-over-quarter.
- 11 funds opened new Larimar Therapeutics positions in Q4 2020 and 6 closed out, a net change of +5 holders.
- The largest Larimar Therapeutics buyer in Q4 2020 was Logos Global Management, an estimated $7.72M added.
- The largest Larimar Therapeutics seller in Q4 2020 was Sphera Funds Management, an estimated $5.19M sold.
Based on aggregated 13F filings for Q4 2020.